Skip to main content

Table 3 Univariate analysis for fracture-free survival in patients who received curettage for GCTBs of the extremities

From: Risk factors of fracture following curettage for bone giant cell tumors of the extremities

Variable No. of patients (n = 284) 1-year fracture-free survival (95% CI) (%) P value
Sex 0.707
 Male 131 96.9 (92.1–98.8)  
 Female 153 97.4 (93.2–99.0)  
Age (years) 0.978
  < 30 140 97.1 (92.6–98.9)  
  ≥ 30 144 97.2 (92.8–99.0)  
Site 0.0005a
 Femur 107 92.5 (85.8–96.2)  
 Others 177 100.0  
Campanacci classification 0.424
 Stage I, II 227 96.9 (93.7–98.5)  
 Stage III 57 98.2 (88.6–99.8)  
Pathological fracture at presentation 0.048a
 No 267 97.8 (95.1–99.0)  
 Yes 17 88.2 (63.2–97.0)  
Denosumab administration 0.952
 No 254 97.2 (94.3–98.7)  
 Yes 30 96.7 (79.8–99.5)  
Previous surgery 0.858
 No 251 96.8 (93.8–98.4)  
 Yes 33 100.0  
Bone grafting 0.003a
 No 125 94.4 (88.7–97.3)  
 Yes 159 99.4 (95.7–99.9)  
Local adjuvant therapy 0.502
 No 37 94.6 (80.8–98.6)  
 Yes 247 97.6 (94.7–98.9)  
  1. aStatistically significant. GCTB Giant cell tumor of bone, CI Confidence interval